A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Phase 2

Completed

Conditions: Graves' Disease

Interventions: Drug: CFZ533

Registration Number: NCT02713256

Lead Sponsor: Novartis Pharmaceuticals

Brief Summary: An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 15

Inclusion Criteria

Male and female patients 18 to 65 years of age included.
Women of child-bearing potential must be willing to use highly effective methods of contraception during the study treatment epoch and for 12 weeks after the last study treatment.
Graves' hyperthyroidism, with the following labs measured at screening:
TSH<LLN and either FT3>ULN or FT4> ULN and
TRAb ≥ 2.5 IU/L
Patients must weigh at least 40 kg to participate in the study

Key

Exclusion Criteria

History of treatment of Graves' disease with radio-iodine ablation or thyroidectomy and/or current treatment with anti-thyroid drugs (methimazole or propylthiouracil) within one week of starting the study treatment
History of hyperthyroidism not caused by Graves' disease (e.g. toxic multinodular goiter, autonomous thyroid nodule, or acute inflammatory thyroiditis) and/or history or presence of thyroid storm (fever, profuse sweating, vomiting, diarrhea, delirium, severe weakness, seizures, markedly irregular heartbeat, yellow skin and eyes (jaundice), severe low blood pressure, and coma).
Previous treatment with a B cell-depleting biologic agent or any other immune-modulatory biologic agent within 5 half-lives (experimental or approved).
History of recurrent clinically significant infection or of recurrent bacterial infections with encapsulated organisms.
History of primary or secondary immunodeficiency, including a positive HIV (ELISA and Western blot) test result.
History or evidence of tuberculosis by either of the following tests:
Positive PPD skin test (size of induration measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5mm or according to local practice/guidelines) OR
Positive QuantiFERON TB-Gold test
Plans for immunization with a live vaccine within a 2-month period before enrollment or during the study period.
Treatment with immunomodulatory drugs, such as cyclosporine A, methotrexate, and/or cyclophosphamide within 3 months from baseline. Glucocorticosteroid therapy with prednisolone up to 10 mg daily is permitted if patients are on stable dose for more than 3 months before enrollment in the study.
Pregnant, breastfeeding females, and women of child bearing potential unless they are using highly effective contraception

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CFZ533 10mg/kg	CFZ533	CFZ533 intravenously over approximately one hour

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment	12 week (DAY 85)	Normalization of TSH is defined as TSH level greater than 0.35 mU/L after 12 week treatment (Day 85)
Percentage of Participants Whose Total Triiodothyronine (Total T3) Levels Decrease After 12 Week Treatment	12 week (DAY 85)	Percentage of participants whose total triiodothyronine (total T3) levels decrease after 12 week treatment. A decrease is when total T3 level is below Upper limit of normal (ULN) ≤ 2.79 nmol/L
Percentage of Participants Whose Free Thyroxine (Free T4) Levels Decrease After 12 Week Treatment	12 week (DAY 85)	Percentage of participants whose free thyroxine (free T4) levels decrease after 12 weeks of treatment (DAY85). A decrease is when free T4 level is below Upper limit of normal (ULN) ≤ 22.7 pmol/L)